Arkolith/Insider Trading/STRO/Form 4

Chung Jane

Chief Executive Officer, DirectorSUTRO BIOPHARMA, INC. (STRO) · full profile →Form 4 · filed Mar 3, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
10
5 non-derivative · 5 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 2, 2026Tax withholding(F)3K$20.55$57K21K
Mar 2, 2026Option exercise(M)8K—$024K
Mar 1, 2026Tax withholding(F)1K$20.47$26K16K
Mar 1, 2026Option exercise(M)3K—$017K
Mar 1, 2026Option exercise(M)688—$015K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 2, 2026Grant(A)175K—$0175K
Mar 2, 2026Option exercise(M)8K—$023K
Mar 2, 2026Grant(A)40K—$040K
Mar 1, 2026Option exercise(M)3K—$05K
Mar 1, 2026Option exercise(M)688—$0688

Transaction Codes

F
Shares withheld for taxes
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001872398-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML